메뉴 건너뛰기




Volumn 4, Issue 10, 2006, Pages 1248-1254

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn's Disease

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CIPROFLOXACIN; INFLIXIMAB; METHOTREXATE; METRONIDAZOLE; PREDNISONE;

EID: 33749432435     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.06.025     Document Type: Article
Times cited : (575)

References (20)
  • 1
    • 0030954732 scopus 로고    scopus 로고
    • A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
    • Targan S.R., Hanauer S.B., van Deventer S.J.H., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
    • (1997) N Engl J Med , vol.337 , pp. 1029-1035
    • Targan, S.R.1    Hanauer, S.B.2    van Deventer, S.J.H.3
  • 2
    • 0037018761 scopus 로고    scopus 로고
    • Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial
    • Hanauer S.B., Feagan B.G., Lichtensein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
    • (2002) Lancet , vol.359 , pp. 1541-1549
    • Hanauer, S.B.1    Feagan, B.G.2    Lichtensein, G.R.3
  • 3
    • 0033529049 scopus 로고    scopus 로고
    • Infliximab for the treatment of fistulas in patients with Crohn's disease
    • Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
    • (1999) N Engl J Med , vol.340 , pp. 1398-1405
    • Present, D.H.1    Rutgeerts, P.2    Targan, S.3
  • 4
    • 10744221312 scopus 로고    scopus 로고
    • Infliximab maintenance therapy for fistulizing Crohn's disease
    • Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
    • (2004) N Engl J Med , vol.350 , pp. 876-885
    • Sands, B.E.1    Anderson, F.H.2    Bernstein, C.N.3
  • 5
    • 10744224387 scopus 로고    scopus 로고
    • Comparison of scheduled and episodic treatment strategies in Crohn's disease
    • Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies in Crohn's disease. Gastroenterology 126 (2004) 402-413
    • (2004) Gastroenterology , vol.126 , pp. 402-413
    • Rutgeerts, P.1    Feagan, B.G.2    Lichtenstein, G.R.3
  • 6
    • 3042579454 scopus 로고    scopus 로고
    • Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
    • Hanauer S.B., Wagner C.L., Bala A., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
    • (2004) Clin Gastroenterol Hepatol , vol.2 , pp. 542-553
    • Hanauer, S.B.1    Wagner, C.L.2    Bala, A.3
  • 7
    • 0037434552 scopus 로고    scopus 로고
    • Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    • Baert F., Norman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Eng J Med 348 (2003) 601-608
    • (2003) N Eng J Med , vol.348 , pp. 601-608
    • Baert, F.1    Norman, M.2    Vermeire, S.3
  • 8
    • 0037379792 scopus 로고    scopus 로고
    • Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized trial
    • Farrell R.J., Alsahli M., Jeen Y.-T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized trial. Gastroenterology 124 (2003) 917-924
    • (2003) Gastroenterology , vol.124 , pp. 917-924
    • Farrell, R.J.1    Alsahli, M.2    Jeen, Y.-T.3
  • 9
    • 0036269445 scopus 로고    scopus 로고
    • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    • St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451-1459
    • (2002) Arthritis Rheum , vol.46 , pp. 1451-1459
    • St Clair, E.W.1    Wagner, C.L.2    Fasanmade, A.A.3
  • 10
    • 0019319257 scopus 로고
    • A simplified index of Crohn's disease activity
    • Harvey R.F., and Bradshaw J.M. A simplified index of Crohn's disease activity. Lancet 1 (1980) 514
    • (1980) Lancet , vol.1 , pp. 514
    • Harvey, R.F.1    Bradshaw, J.M.2
  • 11
    • 4744375545 scopus 로고    scopus 로고
    • Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
    • Daperno M., D'Haens G., Van Assche G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004) 505-512
    • (2004) Gastrointest Endosc , vol.60 , pp. 505-512
    • Daperno, M.1    D'Haens, G.2    Van Assche, G.3
  • 12
    • 71249119542 scopus 로고    scopus 로고
    • Relationship between infliximab pharmacokinetics and improvement in Crohn's disease
    • (abstract)
    • Fasanmade A., Olson A., Bao W., et al. Relationship between infliximab pharmacokinetics and improvement in Crohn's disease. (abstract). Gastroenterlogy 122 (2002) W1364
    • (2002) Gastroenterlogy , vol.122
    • Fasanmade, A.1    Olson, A.2    Bao, W.3
  • 13
    • 26644433889 scopus 로고    scopus 로고
    • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
    • Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
    • (2005) Lancet , vol.366 , pp. 1367-1374
    • Reich, K.1    Nestle, F.O.2    Papp, K.3
  • 14
    • 27944453865 scopus 로고    scopus 로고
    • Endoscopic and histological evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease
    • Geboes K., Rutgeerts P., Opdenakker G., et al. Endoscopic and histological evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 21 (2005) 1741-1754
    • (2005) Curr Med Res Opin , vol.21 , pp. 1741-1754
    • Geboes, K.1    Rutgeerts, P.2    Opdenakker, G.3
  • 15
    • 24644474678 scopus 로고    scopus 로고
    • Correlation of C-reactive protein with clinical, endoscopic, and radiological activity in inflammatory bowel disease
    • Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, and radiological activity in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 707-712
    • (2005) Inflamm Bowel Dis , vol.11 , pp. 707-712
    • Solem, C.A.1    Loftus, E.V.2    Tremaine, W.J.3
  • 16
    • 0036161216 scopus 로고    scopus 로고
    • A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    • Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
    • (2002) Gastroenterology , vol.122 , pp. 512-530
    • Sandborn, W.J.1    Feagan, B.G.2    Hanauer, S.B.3
  • 17
    • 11144354315 scopus 로고    scopus 로고
    • Sustained improvement over two years in physical function, structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
    • Maini R.N., Breedveld F.C., Kalden J.R., et al. Sustained improvement over two years in physical function, structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
    • (2004) Arthritis Rheum , vol.50 , pp. 1051-1065
    • Maini, R.N.1    Breedveld, F.C.2    Kalden, J.R.3
  • 18
    • 0031660364 scopus 로고    scopus 로고
    • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
    • Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
    • (1998) Arthritis Rheum , vol.41 , pp. 1552-1563
    • Maini, R.N.1    Breedveld, F.C.2    Kalden, J.R.3
  • 19
    • 27444448124 scopus 로고    scopus 로고
    • Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis
    • Sany J., Kaiser M.J., Jorgensen C., et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 64 (2005) 1647-1649
    • (2005) Ann Rheum Dis , vol.64 , pp. 1647-1649
    • Sany, J.1    Kaiser, M.J.2    Jorgensen, C.3
  • 20
    • 24144491310 scopus 로고    scopus 로고
    • Variability factors in the clinical response to recombinant antibodies and IgG Fc- containing fusion proteins
    • Waiter H. Variability factors in the clinical response to recombinant antibodies and IgG Fc- containing fusion proteins. Expert Opin Biol Ther 5 Suppl 1 (2005) S29-S36
    • (2005) Expert Opin Biol Ther , vol.5 , Issue.SUPPL. 1
    • Waiter, H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.